MONROVIA, Calif.—STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, has closed the previously announced underwritten public offering of 1,999,850 shares of its common stock, which includes the full exercise of the underwriter’s option to purchase up to an additional 260,850 shares, at a price to the public of $39 per share. The gross proceeds of the offering, before deducting underwriting commissions and offering expenses, were $77,994,150.

Canaccord Genuity acted as the sole book-running manager for the offering. All shares of the common stock offered by STAAR were offered pursuant to an effective shelf registration statement (including a prospectus) on Form S-3 previously filed with the Securities and Exchange Commission (SEC).